1 completed, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow TargeGen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD TG100801 - Macular Degeneration, Choroidal Neovascularization | Phase 2 | Terminated | TargeGen | 7 | 2007-07-01 | 2010-03-29 |
| Safety of TG100-115 for Heart Attack Treated With Angioplasty TG100-115 - Myocardial Infarction | Phase 1 / Phase 2 | Completed | TargeGen | 100 | 2005-01-01 | 2008-05-20 |
Choroidal Neovascularization (1) · Macular Degeneration (1) · Myocardial Infarction (1)
3-(2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl)phenol (1) · 4-chloro-3-(5-methyl-3-((4-(2-pyrrolidin-1-ylethoxy)phenyl)amino)-1,2,4-benzotriazin-7-yl)phenol (1)
United States (2)